Crown Bioscience Completes Merger with Indivumed Services

San Diego, USA—February 17, 2025— Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, today announces the complete integration of Indivumed Services. This strategic move, following the acquisition in 2023, solidifies Crown Bioscience's standing in oncology drug research and development. As a result of this merger, the Indivumed Services brand will be fully retired in February 2025.

The merger unifies the strengths of both entities, offering pharmaceutical and biopharmaceutical partners a powerful toolkit of integrated platforms and services, including biospecimen solutions, to enhance the oncology drug development process from discovery through to clinical stages. Crown Bioscience will maintain operations across 11 locations in the United States, Europe, and the Asia-Pacific region and will continue to be dedicated to consistently delivering expanded services and leading research platforms on a global scale.

Media Inquiries:

Crown Bioscience

Sarah Martin-Tyrrell

pr@crownbio.com